Researchers have identified a metabolic biomarker that could be used to track the progression of arrhythmogenic cardiomyopathy – a genetic heart muscle disease that can cause life-threatening ventricular arrhythmias.
In this interview, Mark Bayliss (North Bristol NHS Trust, Southmead Hospital; Bristol, UK) discusses his bioanalytical career and explores the importance of bioanalysis through observations in made in his current research.
Researchers have reported a new blood test that could accurately identify and distinguish active cases of tuberculosis in adults from diseases with similar symptoms in under 1 hour.
Matthew Baker, University of Strathclyde (Glasgow, Scotland), led research for a diagnostic tool that distinguished 87% of blood samples from patients with brain cancer from healthy individuals. This diagnostic tool could improve the speed and accuracy of brain cancer diagnosis.
Scientists from the University of Eastern Finland (Finland) and the University of Oulu (Finland) have published a study that demonstratesshows serum neurofilament levels could be used as a biomarker to discriminate frontotemporal dementia from psychiatric disorders.
In a new study, researchers from Osaka University (Japan) have demonstrated that measuring methylation of microRNA could accurately distinguish individuals with early pancreatic cancer from healthy controls.
In this article, details of the tailored solutions KCAS (KS, USA) offers for flow cytometry are discussed including 13 prequalified biomarker immune monitoring panels for support of clinical trials.
We look at some of the highlights of our Twitter chat (#TalkProteomics), where we questioned panelists John Wilson, Ben Orsburn, Matthias Trost and Eduardo Chicano Gálvez about all things proteomics – from mass spectrometry to drug discovery.
This editorial provides an insight into the advancing field of microsampling as a tool to monitor critically ill patients in the clinic, highlighting the need for further development to ensure patients receive the highest quality of care.
A novel protein has been discovered that could be a useful blood-based biomarker to monitor the progression of inherited Alzheimer’s disease, over a decade before the clinical symptoms appear.